| Drug Name |
Oprelvekin |
| Drug ID |
BADD_D01620 |
| Description |
Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long. However, it displays comparable biological activity compared to the natural IL-11 _in vitro_ and _in vivo_. Oprelvekin works by stimulating megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies of animals with moderate and severe myelosuppression, in addition to compromised hematopoiesis, oprelvekin was shown to potently induce thrombopoiesis and improve platelet nadirs and accelerated platelet recoveries compared to controls. In animal studies, oprelvekin was also shown to regulate intestinal epithelium growth by enhancing healing of gastrointestinal lesions, inhibit adiopegenesis and macrophageal released pro-inflammatory cytokines, and induce acute phase protein synthesis. |
| Indications and Usage |
Indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.[Label] |
| Marketing Status |
approved; investigational |
| ATC Code |
L03AC02 |
| DrugBank ID |
DB00038
|
| KEGG ID |
D05266
|
| MeSH ID |
C105308
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0T1IJ
|
| NDC Product Code |
Not Available |
| UNII |
HM5641GA6F
|
| Synonyms |
oprelvekin | interleukin-11 (2-178) | rhIL-11 | Neumega |
